Kuros Announces Allowance of US Patent for the Local Application of Parathyroid Hormone (PTH) for Bone Healing

By Kuros Biosurgery Ag, PRNE
Monday, July 18, 2011

ZURICH, July 19, 2011 -


Kuros Biosurgery AG, a biotechnology company focused on the
development of novel biomaterials and bioactive-biomaterial
combination products for trauma, wound and spinal indications,
announced today that it has received Notice of Allowance for U.S.
11/679,807 from the U.S. Patent Office. The now allowed application
acknowledges that Kuros has been first in showing that parathyroid
hormone (PTH) when applied locally in a matrix to a bone defect has
the ability to improve bone healing. Kuros has already demonstrated
the clinical utility of this proprietary approach to bone healing
in two large phase II studies in trauma patients which have
reported previously.

Kuros is developing a portfolio of biomaterial, and
bioactive-biomaterial combination, products. The Company’s product
candidates are based on two different matrix technology platforms.
 Kuros’ most advanced products are based on a fibrin matrix
and include KUR-111 and KUR-113 which have achieved positive
results in large Phase II trials for tibial plateau fractures and
tibial shaft fractures respectively.

 Didier Cowling, Chief Executive
Officer at Kuros says: ”This patent will give Kuros broad
protection on the concept of locally applied PTH to improve bone
healing. Obtaining the notice of allowance for this US patent
application further builds on Kuros’ proprietary position in local
treatments for bone generation and healing”.

The Notice of Allowance for US 11/679,807 with its broad scope
of protection follows US 7,247,609, US 6,331,422, US 6,607,740, EP
1 465 989, EP 1 124 590, EP 1 280 566 and patents in many other
countries which protect Kuros` approach with PTH and its
incorporation into matrices for local therapeutic applications.

About Kuros


Kuros is a biotechnology company that is focused on the
development of novel biomaterials and bioactive-biomaterial
combination products for trauma, wound and spinal indications.

Kuros has two biomaterial technology platforms, one based on
fibrin sealants and the other based on its own proprietary
synthetic technology that can mimic fibrin in many of its
attributes.  These materials can be used alone or in
combination with biologically active molecules.

Kuros’ combination products are designed to mimic the body’s
natural healing process. The products consist of fusion proteins of
naturally occurring bioactive factors, covalently incorporated into
fibrin or synthetic matrices. The incorporation of the biologically
active molecules into the injectable matrices aims to maximize
their activity by retention at the site of action. Kuros products
are designed to combine ease of application with localized
delivery.  Kuros has a number of methodologies to achieve the
desired retention and release profiles of the biologically active

Kuros’ has a diverse pipeline of product candidates with its
most advanced product candidates being in trauma and wound

Since its creation, Kuros has raised over $150 million. The
company is located in Zurich, Switzerland.

Press Enquiries

Didier Cowling, CEO +41(0)44-200-56-62
Alistair Irvine, Director of Business Development

For Swiss Media Enquires:
IRF Communications
Martin Meier-Pfister +41(0)43-244-81-40
Jan Gregor +41(0)43-244-81-54

For International Media Enquires:
Citigate Dewe Rogerson
David Dible, Nina Enegren +44(0)207-638-9571


will not be displayed